Navigation Links
New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures
Date:4/10/2009

ATLANTA, April 10 /PRNewswire/ -- Once-daily Keppra XR(TM) (levetiracetam) extended-release tablets are now available in a new dosage strength--750 mg--enabling doctors to simplify patients' treatment plans by decreasing the number of tablets they take each day.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090410/NY97244 )

According to studies published in Epilepsy & Behavior and Neurology, patients are more likely to adhere to their medication regimen when it is taken once daily, and therefore may be more likely to reach the goal of epilepsy therapy--seizure freedom with minimal side effects.

Keppra XR(TM), from UCB, The Epilepsy Company(TM), was approved last year as an add-on therapy for partial-onset seizures in patients who are 16 years of age and older with epilepsy. Keppra XR(TM) is the only extended-release formulation of levetiracetam and cannot be substituted with generic levetiracetam, immediate-release levetiracetam or any other antiepileptic medication at the pharmacy counter.

Keppra XR(TM) was approved by the U.S. Food and Drug Administration (FDA) based on data from an international clinical study of 158 epilepsy patients with partial-onset seizures who added 1,000 mg of Keppra XR(TM) or placebo to their other epilepsy medications once daily. The study consisted of an 8-week baseline period followed by a 12-week treatment period.

  • The study showed that 10.1 percent of Keppra XR(TM) patients experienced complete partial-onset seizure freedom vs. 1.3 percent in the placebo group over the treatment period.
  • Keppra XR(TM) patients experienced a 46.1 median percent reduction in weekly partial-onset seizure frequency versus 33.4 percent in the placebo group.

Keppra XR(TM) is also available in 500 mg tablet strength. Data presented at last year's American Epilepsy Society meeting demonstrated that taking two 750 mg levetiracetam extended-release tablets is the same as taking three 500 mg extended-release tablets.

Treatment with Keppra XR(TM) should be initiated with a dose of 1,000 mg once daily. The daily dosage may be adjusted in increments of 1,000 mg every two weeks, to a maximum recommended dose of 3,000 mg per day.

Keppra XR(TM) Important Safety Information

Keppra XR(TM) extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Keppra XR(TM) causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR(TM) in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR(TM) are expected to be similar to those seen in patients receiving immediate-release Keppra(R) (levetiracetam) tablets.

Keppra(R) immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse reactions observed with Keppra(R) in combination with other AEDs were somnolence, asthenia, infection, and dizziness.

Keppra XR(TM) should be gradually withdrawn to minimize the potential of increased seizure frequency.

Dosing must be individualized according to the patient's renal function status. In patients with end-stage renal disease on dialysis, it is recommended that immediate-release Keppra(R) be used instead of Keppra XR(TM). Please see Keppra.com for Keppra(R) immediate-release tablets full prescribing information.

For full prescribing information, please see www.KeppraXR.com.

In order to ensure patient access to this valuable medication in the U.S., UCB is initiating a co-pay support program. For more information, contact U.S. UCB Medical Information at 1-866-822-0068 (press 9).

About Epilepsy

Epilepsy is a chronic neurological disorder affecting approximately three million people in the U.S.--making it more common than multiple sclerosis and Parkinson's disease combined. It is caused by abnormal, excessive electrical discharges of the nerve cells, or neurons, in the brain. Epilepsy is characterized by a tendency to have recurrent seizures and defined by two or more unprovoked seizures. There are many different seizure types and epileptic syndromes. Less than half of patients (47 percent) will attain seizure control with their first AED, and more than 30 percent will continue to experience seizures despite trying two or more AEDs. This highlights the ongoing need for the development of new AEDs. For more information about epilepsy, visit www.epilepsyfoundation.org, www.epilepsy.com, or www.epilepsyadvocate.com.

Further Information

Andrea Levin, Public Relations Manager, CNS, UCB U.S.

T +1.770.970.8352, Andrea.levin@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10 000 people in over 40 countries, UCB aims to achieve revenues of 3.3 billion euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB). UCB U.S. headquarters is based in Atlanta.


'/>"/>
SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures
2. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
3. High dosage brachytherapy obtains excellent results in head and neck tumors
4. Tools for more accurate dosage of drugs against HIV/AIDS and malaria
5. Genetics May Help Fine-Tune Warfarin Dosage
6. Comar, Inc. Launches AccuCup(TM) - A Printed Dosage Cup for Use in General and Pediatric Markets
7. Attorney General Corbett Announces $36.7 Million Multi-State Settlement With CVS/Caremark in National Dosage-Switching Investigation
8. FDA approves additional dosage strengths of Vyvanse
9. Capsugels Liquid Dosage Form Technology Utilized by Eight of the Top 10 Pharmaceutical Companies
10. Vitamin Es lack of heart benefit linked to dosage
11. Recovery Resources to Honor Ulmer & Berne Attorney Inajo Davis Chappell with the Helen K. Jones Woman of Strength Memorial Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Fargo, ND (PRWEB) , ... May 25, 2016 , ... ... get easier. In early June 2016, Kashi®, a maker of whole grain cereals and ... with a Certified Transitional ingredient: hard red winter wheat processed by Hesco/Dakota Organic ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Stern ... firm will be selling the device branded as Stern’s Real Time Monitoring ... to bedbugs to the hotel and motel industry, colleges for use in dormitories, shelters, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is launching a Kickstarter ... refillable hanging wipe dispenser. The campaign kick-off video is located via this link ... 2016. The goal is to raise $1,000 per day for a total of $25,000. ...
(Date:5/24/2016)... ... , ... To better understand the impact of lung cancer in women, the ... lung cancer. Today, the Lung Association announced Sharad Goyal, MD , as the recipient ... the American Lung Association’s LUNG FORCE initiative, which raises awareness of the impact of ...
(Date:5/24/2016)... Rosa, California (PRWEB) , ... May 24, 2016 ... ... (PHM) technology, debuted a new corporate identity and website at its “Transforming Outcomes” ... website, and other marketing enhancements reflect i2i’s ongoing success to set the market ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... FLINT, Mich. , May 23, 2016 Diplomat ... the third annual Fellowship and Internship programs. The hands-on ... 12. The full-time, paid Fellowship ... Flint, Michigan . Fellows and interns are ... downtown Flint at the Riverfront ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... , May 23, 2016 The World Health ... PrePex device to include adolescents aged 13 years, and ... can be offered for adult and adolescent males in the ... . PrePex was the first male circumcision device to ... MedTech,s CEO, Eddy Horowitz said: " The ...
Breaking Medicine Technology: